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To develop an immunotherapeutic vaccine for treatment of allergic rhinitis, we 
developed a controlled release formulation of Cryj1, a major Japanese cedar pollen 
allergen, with immunostimulatory potency. Two sets of hexapod-like structured DNA 
(hexapodna) were prepared using six oligodeoxynucleotides (ODNs) each, including 
ODNs with an unmethylated cytosine-phosphate-guanine (CpG) sequence (CpG motif), 
to obtain an immunostimulatory DNA hydrogel (sDNA hydrogel). A 
non-immunostimulatory DNA hydrogel (nsDNA hydrogel) was also prepared using 
ODNs with no CpG motifs. The sDNA hydrogel was more effective than its 
components or the nsDNA hydrogel for production of interleukin (IL)-12 after addition 
to murine macrophage-like RAW264.7 cells or after intranasal administration to mice. 
Then, a Cryj1-loaded sDNA hydrogel (Cryj1/sDNA hydrogel) formulation was 
prepared by mixing solutions containing both Cryj1 and hexapodna. Cryj1 was slowly 
released from the sDNA hydrogel in phosphate-buffed saline. After intranasal 
administration of the fluorescein isothiocyanate (FITC)-labeled Cryj1/sDNA hydrogel 
in mice, FITC-Cryj1 was retained in the nasal cavity for a longer period than 
FITC-Cryj1 mixed with hexapodna in solution. Intranasal immunization of mice with 
the Cryj1/sDNA hydrogel resulted in high levels of Cryj1-specific IgG in nasal lavage 
fluid (NFL), IL-12 and interferon- release from spleen cells after re-stimulation with 
Cryj1 when compared with intranasal immunization with the other formulations 
examined. These results indicate that the self-gelling immunostimulatory DNA hydrogel 
is an effective formulation for controlled induction of allergen-specific immune 
responses. 
 






Toll-like receptor 9 (TLR9) is the receptor for DNA containing the unmethylated 
cytosine-phosphate-guanine (CpG) sequence, or CpG motif (CpG DNA). Ligation of 
TLR9 results in the release of tumor necrosis factor (TNF)-, interleukin (IL)-12, and 
other proinflammatory cytokines, and in the stimulation of humoral and cellular 
immune responses [1-4]. CpG DNA-induced secretion of Th1 cytokines such as IL-12 
and interferon (IFN)- converts uncommitted T-cells (Th0) to T helper 1 cells (Th1), 
which suppress the function of Th2 cells [5]. At least two mechanisms for CpG DNA as 
an allergy vaccine adjuvant are known. The first is reduced Th2 responses manifested as 
reduced activation of basophils and eosinophils, and reduced class-switching of B-cells 
to produce IgE [4, 5]. The second is CpG DNA-induced humoral immunity such as 
competition of allergen-specific IgG and IgA with IgE for allergen binding [6, 7]. 
Previous clinical studies have shown that subcutaneous injection of CpG DNA 
conjugated with ragweed pollen antigen was effective for preventing ragweed seasonal 
allergic rhinitis in humans [8, 9].  
 In addition to its immunostimulatory activity, DNA possesses various drug-like 
characteristics, including high water solubility, ease of chemical synthesis on a large 
scale, and high stability and biodegradability [10]. DNA also can be used as a drug 
delivery system through conjugation with low-molecular-weight compounds or 
formation of hydrogels [11]. We previously reported that doxorubicin (DXR) 
intercalated into CpG motif-containing plasmid DNA was delivered to colon carcinoma 
cells in the mouse liver where it efficiently inhibited tumor growth [12]. We also 
reported that DXR loaded in CpG DNA hydrogels was gradually released and 
effectively inhibited the growth of subcutaneous tumors [13]. We extended these results 
and recently developed a novel method to prepare a ligase-free, self-gelling injectable 
DNA hydrogel. Intradermal injection of this CpG DNA hydrogel loaded with 
ovalbumin as a model antigen showed high potency and low toxicity as a vaccine 
adjuvant [14]. Because this self-gelling DNA hydrogel can be administered to cavities 
as a spray, it could be a useful delivery system for intranasal vaccines.  
 Allergic rhinitis is a global health problem affecting 10–20% of the population 
[15]. The incidence of allergic rhinitis caused by Japanese cedar pollen (JCP) is 
estimated to be 30–40% among adult Japanese population [16]. Although symptomatic 
therapy with pharmacological agents has been a common treatment for allergic rhinitis 
thus far, considerable attention has been paid to allergen-specific immunotherapies that 
induce long-term remission [17]. At present, allergy immunotherapy involves 3–5 years 
of subcutaneous injections, but a short-term and self-administrable mucosal 
immunotherapy such as intranasal or sublingual vaccines will be ideal for patients [18]. 
Immunotherapy with an immunostimulatory adjuvant such as CpG DNA is expected to 
induce effective immune responses for shorter mucosal immunotherapy. 
 To the best of our knowledge, this is the first report of a newly designed 
self-gelling immunostimulatory CpG DNA hydrogel loaded with Cryj1, a major JCP 
allergen (Cryj1/sDNA hydrogel). The physicochemical properties and biological 
activity of the Cryj1/sDNA hydrogel were examined after intranasal administration to 
mice, to evaluate the potential of the sDNA hydrogel as an intranasal delivery system to 
induce immunotherapeutic effects against allergic rhinitis. 
 
 
Materials and Methods 
 Chemicals. RPMI 1640 medium was obtained from Nissui Pharmaceutical 
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(Tokyo, Japan). Fetal bovine serum (FBS) was obtained from MP Biomedicals 
(Eschwege, Germany). Cryj1 was extracted from JCP by stirring in 0.125 M NaHCO3 
solution (pH8.0) for 1 h at room temperature, and the extract was purified by 
centrifugation at 15,000 g for 30 min and ultrafiltration of the supernatant using a 
10-kDa filter. The content of purified Cryj1 was determined by an ELISA kit for Cryj1 
purchased from Nichinichi Pharmaceutical (Mie, Japan). Cryj1 was labeled with 
fluorescein isothiocyanate (FITC; fluorescein isothiocyanate isomer 1, Sigma-Aldrich, 
St. Louis, MO, USA) to obtain FITC-Cryj1. All other chemicals were of the highest 
grade available and used without further purification. 
 Cell culture. The murine macrophage-like cell line RAW264.7 was obtained from 
the American Type Culture Collection (Rockville, MD, USA). Cells were grown in 
RPMI 1640 medium supplemented with 10% heat-inactivated FBS, 0.15% NaHCO3, 
100 units/ml penicillin, 100 g/ml streptomycin, and 2 mM L-glutamine at 37°C in 
humidified air containing 5% CO2. 
 Animals. Male BALB/c mice (5 weeks old) were purchased from Japan SLC, Inc. 
(Shizuoka, Japan). Animals were maintained under conventional housing conditions. All 
animal experiments were approved by the Animal Experimentation Committee of the 
Graduate School of Pharmaceutical Sciences, Kyoto University.  
 Preparation of polypodna and DNA hydrogel loaded with Cryj1. All 
phosphodiester oligodeoxynucleotides (ODNs) were purchased from Integrated DNA 
Technologies, Inc. (Coralville, IA, USA). The hexapodna and DNA hydrogel was 
designed and prepared using the ODNs as reported in our previous study [14]. In brief, 
three immunostimulatory hexapodna (sHexa) with potent CpG motifs, and three 
non-immunostimulatory hexapodna (nsHexa) with no CpG motifs were prepared. 
sHexa-1 and sHexa-2 were designed to have complementary 5′-ends. nsHexa-1 and 
nsHexa-2 were also designed similarly. The sequence of sHexa-3 was identical to that of 
sHexa-2 except for their 5′-ends, and sHexa-3 did not have a 5′-end complementary to 
sHexa-1. 
 The formation of hexapodna was confirmed by 6% polyacrylamide gel 
electrophoresis (PAGE). Immunostimulatory and non-immunostimulatory DNA 
hydrogels (sDNA hydrogel and nsDNA hydrogel, respectively) were obtained by 
mixing equimolar amounts of sHexa-1 and sHexa-2 or nsHexa-1 and nsHexa-2, 
respectively, at an initial concentration of 0.1 or 0.3 mM DNA (7 µg/µl DNA or 22 
µg/µl DNA, respectively). A hexapodna solution was also prepared as a control by 
mixing sHexa-1 and sHexa-3. To prepare the Cryj1-loaded DNA hydrogels 
(Cryj1/sDNA hydrogel and Cryj1/nsDNA hydrogel), Cryj1 was added to sHexa-1 and 
sHexa-2 or nsHexa-1 and nsHexa-2, respectively, before mixing. Hydrogel formation 
was briefly confirmed by adding a solution containing blue dextran (Sigma-Aldrich), 
which does not instantly diffuse into hydrogels, or by 6% PAGE as previously reported 
[14].  
 Observation of the inner structure of the sDNA hydrogel and Cryj1/sDNA 
hydrogel by scanning electron microscopy. The inner structures of the 0.1 mM and 
0.3 mM Cryj1/sDNA hydrogels were observed using a field-emission scanning electron 
microscope (FE-SEM: S4700; HITACHI, Japan) as previously described [14]. In brief, 
the samples were fixed with 2% glutaraldehyde at room temperature overnight, 
dehydrated with increasing concentrations of ethanol that was then replaced with butyl 
alcohol, and then freeze-dried. The dried material was cracked with a knife, and the 
inner structure of the DNA hydrogels was observed. 
 Cryj1 release from DNA hydrogel in vitro. FITC-Cryj1 was mixed with 
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sHexa-1 and sHexa-2 solutions, and 0.1 mM and 0.3 mM sDNA hydrogels containing 
FITC-Cryj1 were prepared as described above. As a control, FITC-Cryj1 was mixed 
with sHexa-1 and sHexa-3 solutions, and 0.1 mM or 0.3 mM sHexa solution containing 
FITC-Cryj1 (FITC-Cryj1+sHexa) was prepared. Then, the FITC-Cryj1/sDNA hydrogel 
or FITC-Cryj1+sHexa was placed into the upper chamber of a Transwell (Product#3460, 
0.4-μm pore size; Corning Inc., Corning, NY, USA), and 1000 μl of PBS was added into 
the bottom chamber, followed by incubation at 37°C. At predetermined time points, 
fluorescence images of FITC-Cryj1/sDNA hydrogel were obtained using LAS3000 
system (Fujifilm, Tokyo, Japan), and the fluorescence intensity of the receiver solution 
was measured in a Wallac1420 ARVO MX-2 Multilabel Counter (Perkin-Elmer, Boston, 
MA, USA). 
IL-12 release from RAW264.7 cells. RAW264.7 cells were plated on 24-well 
culture plates at a density of 5  105 cells/ml (2.5  105 cells/well) and cultured for 24 h 
before use. ssODN (a mixture of CpG Hex.-1-1 and CpG Hex.-3-1), sHexa (a mixture 
of sHexa-1 and sHexa-3), sDNA hydrogel, nsDNA hydrogel, ssODN with Cryj1 
(Cryj1+ssODN), sHexa with Cryj1 (Cryj1+sHexa), sDNA hydrogel or nsDNA hydrogel 
physically mixed with Cryj1 (Cryj1+sDNA hydrogel or Cryj1+nsDNA hydrogel, 
respectively), or Cryj1/sDNA hydrogel was diluted in Opti-MEM buffer (Life 
Technologies, Carlsbad, CA, USA) to a concentration of 100 g/ml DNA and 20 g/ml 
Cryj1, before it was added to the cells. The cells were incubated for 16 h, and the 
supernatants were collected and stored at -80C until assayed. The level of IL-12p40 in 
the supernatant was determined by enzyme-linked immunosorbent assay (ELISA) by 
using an OptEIA
TM
 set (BD Biosciences, San Diego, CA, USA). 
 Cellular uptake of FITC-Cryj1 by RAW264.7 cells. RAW264.7 cells were 
plated on 96-well culture plates at a density of 5  105 cells/ml (5  104 cells/well) and 
cultured for 24 h before use. The cells were then washed twice with 100 l of PBS and 
incubated with FITC-Cryj1, FITC-Cryj1 with ssODN (FITC-Cryj1+ssODN), 
FITC-Cryj1 with sHexa (FITC-Cryj1+sHexa), FITC-Cryj1 with sDNA hydrogel 
(FITC-Cryj1+sDNA hydrogel), or FITC-Cryj1/sDNA hydrogel at 37°C or 4°C. At 3 h 
after addition, the cells were washed three times with 200 l PBS. Then, fluorescent 
intensity of the cells was determined by flow cytometry (FACSCalibur; BD Biosciences, 
San Jose, CA, USA) using CellQuest software (version 3.1; BD Biosciences), and the 
mean fluorescence intensity (MFI) was calculated as an indicator of the cellular uptake 
of FITC-Cryj1. 
 Distribution and clearance of Cryj1/DNA hydrogel after intranasal 
administration to mice. A mixed solution of sHexa and FITC-Cryj1 
(FITC-Cryj1+sHexa) (50 g DNA, 10 g Cryj1/mouse) or FITC-Cryj1/sDNA hydrogel 
(50 g DNA, 10 g Cryj1/mouse) was intranasally (i.n.) administered to BALB/c mice 
by using a micropipette, under anesthesia with pentobarbital at a concentration of 0.1 
mM DNA. At 0.5, 3, and 6 h after administration, the mice were killed, and nasal lavage 
fluid (NFL) was collected by washing the nasal cavity with 800 l of PBS. The 
concentration of DNA in the NFL was measured at 260 nm by NanoDrop™ 2000 
(Thermo Scientific, Waltham, MA, USA), and the concentration of Cryj1 was evaluated 
by measuring the fluorescence intensity of the samples in a Wallac1420 ARVO MX-2 
Multilabel Counter. In different sets of mice, the distribution of DNA was observed 
using LAS3000 after staining of DNA remaining in the nasal cavity with SYBR Gold 
(Life Technologies, Carlsbad, CA, USA).  
 IL-12 production in serum and NFL after intranasal administration of the 
sDNA hydrogel to mice. Saline, ssODN, or sDNA hydrogel was administered i.n. to 
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BALB/c mice by using a micropipette at a dose of 50 g DNA/mouse (DNA 
concentration: 0.1 mM, 6.8 l/mouse) under anesthesia with pentobarbital. At 6 h after 
administration, the mice were killed, and their blood was collected to obtain serum after 
centrifugation. NFL was also collected by washing the nasal cavity with 1000 l of PBS. 
The level of IL-12p40 in the serum and NFL was determined by ELISA. 
IL-12 and IFN- release from spleen cells after immunization of mice. Cryj1, 
Cryj1 and ssODN (Cryj1+ssODN), Cryj1 and sHexa (Cryj1+sHexa), or the 
Cryj1/sDNA hydrogel was administered i.n. to BALB/c mice at a dose of 50 g DNA 
and 10 g Cryj1/mouse (DNA concentration: 0.1 mM) under anesthesia with 
pentobarbital. A different set of mice received a subcutaneous (s.c.) injection of Cryj1 at 
a dose of 10 g/mouse under anesthesia with isoflurane. The mice were immunized 
twice on days 0 and 14. At 14 days after the second immunization, the mice were killed 
and serum, spleen, and NFL were collected. Spleen cells were purified and cultured in 
the presence of Cryj1 (2.5 g/ml) in 12-well culture plates for 3 days. The concentration 
of IL-12p40 in the supernatant was determined as described above. The concentration of 
IFN- in the supernatant was determined by ELISA by using an Mouse IFN gamma 
ELISA Ready-SET-Go!® (eBioscience, San Diego, CA, USA). 
Cryj1-specific antibodies in serum and NFL of mice after immunization. The 
titers of Cryj1-specific IgG in serum and NFL were measured by ELISA. Briefly, 
ELISA plates were coated with Cryj1 in PBS overnight at 4°C (2.5 μg/ml Cry j 1). After 
coating, 1000-fold diluted serum samples and non-diluted NFL samples were added to 
the plates and incubated at 37°C for 2 h. After washing, HRP-labeled anti-mouse IgG 
(Wako Pure Chemical, Osaka, Japan) was added, and the samples were incubated at 
37°C for 1 h. After additional washing, o-phenylenediamine substrate was added, and 
the OD was measured at 450 nm. Anti-Cryj1 mouse monoclonal antibody (Funakoshi, 
Tokyo, Japan) was used as a standard for Cryj1-specific IgG. 
IgE in serum of mice after nasal immunization. Cryj1, Cryj1 and ssODN 
(Cryj1+ssODN), Cryj1 and sHexa (Cryj1+sHexa), or the Cryj1/sDNA hydrogel was 
administered i.n. to BALB/c mice at a dose of 50 g DNA and 10 g Cryj1/mouse 
(DNA concentration: 0.1 mM) under anesthesia with pentobarbital. The mice were 
immunized three times on days 0, 7 and 14. At 14 days after the third immunization, the 
mice were killed and serum was collected. The concentration of IgE in serum was 
determined by ELISA using an OptEIA
TM
 set (BD Biosciences). 
 Statistical analysis. Differences were statistically evaluated by one-way analysis 
of variance (ANOVA) followed by the Tukey-Kramer test for multiple comparisons and 





Formation of Cryj1/sDNA hydrogel. Fig. 1 shows typical FE-SEM images of 
the inner structure of the sDNA hydrogel and Cryj1/sDNA hydrogel. The images 
indicate that the sDNA hydrogel has a highly ordered structure with plenty of space. 
The inner structure of Cryj1/sDNA hydrogel was thicker than that of sDNA hydrogel, 
suggesting that Cryj1 is uniformly bound to the DNA network. The structure of 
Cryj1/sDNA hydrogel became denser with an increasing DNA concentration.  
 
Sustained release of Cryj1 from sDNA hydrogel. To visualize Cryj1 release, 
FITC-labeled Cryj1 was encapsulated into sDNA hydrogels prepared at a concentration 
of 0.1 or 0.3 mM DNA. Fig. 2a shows fluorescence images of the FITC-Cryj1/sDNA 
hydrogel placed into the upper chamber of the Transwell. The images clearly show that 
FITC-Cryj1 was slowly released from the sDNA hydrogel. When a 0.3 mM sDNA 
hydrogel was applied, FITC-Cryj1 remained at the location where the hydrogel was 
placed for at least 1 h. In contrast, FITC-Cryj1 quickly diffused away soon after a 0.1 
mM sDNA hydrogel was applied. These results suggest that the shape of the 0.3 mM 
sDNA hydrogel was maintained longer than that of the 0.1 mM sDNA hydrogel. No 
significant differences in the fluorescence images were observed between the two 
groups at 6 h or later. The fluorescence intensity of the solution in the lower chamber 
also showed that FITC-Cryj1 was gradually released from the sDNA hydrogel, whereas 
it was rapidly released from sHexa solution within 2 h (Fig. 2b). The initial release of 
Cryj1 from the 0.1 mM sDNA hydrogel was faster than that from the 0.3 mM sDNA 
hydrogel, but no significant difference between the 0.1 mM and 0.3 mM hydrogels was 
observed in the release profile at 6 h or later. 
 
IL-12 release from RAW264.7 cells by the Cryj1/sDNA hydrogel. To investigate 
the effect of sDNA hydrogel formation and Cryj1 loading into the sDNA hydrogel on 
the production of an innate immune response, IL-12 release from RAW264.7 cells was 
examined after addition of a variety of components of the sDNA hydrogel with or 
without Cryj1. Fig. 3 shows the IL-12 concentrations in the supernatant of the 
RAW264.7 cells at 16 h after addition of Cryj1 (20 g/ml), DNA (100 g/ml) or their 
combination. The IL-12 secretion induced by the Cryj1/sDNA hydrogel was 
significantly greater (P < 0.05) than that induced by Cryj1+ssODN or Cryj1+sHexa. In 
addition, Cryj1+sHexa induced higher secretion of IL-12 than Cryj1+ssODN. The 
nsDNA hydrogel with no CpG motifs induced only low IL-12 secretion in the medium. 
There was no significant difference between sDNA hydrogel and Cryj1+sDNA hydrogel, 
suggesting that Cryj1 itself hardly has any effect on IL-12 induction. 
Fig. 1. FE-SEM images of the 
inner structure of sDNA hydrogel 
and Cryj1/sDNA hydrogel. Left, 
sDNA hydrogel (0.3 mM DNA); 
center, Cryj1/sDNA hydrogel (0.3 
mM DNA); right, Cryj1/sDNA 
hydrogel (0.1 mM DNA). Images 
were taken using a field-emission 
scanning electron microscope at 
low (2000, upper panels) and 






















Fig. 2. Cryj1 release from sDNA 
hydrogel. FITC-Cryj1 was loaded 
into the sDNA hydrogel or mixed 
with sHexa solution at a ratio of 1 
g Cryj1/5 g DNA, and then 
placed into the upper chamber of 
the Transwell (0.4-μm pore size) 
with the bottom chamber 
containing PBS, followed by 
incubation at 37°C. (a) The 
fluorescence images of the 
FITC-Cryj1/sDNA hydrogel 
prepared at DNA concentrations 
of 0.1 mM (left) and 0.3 mM 
(right) were photographed at the 
indicated times. (b) The 
concentration of FITC-Cryj1 
released from 0.1 mM or 0.3 mM 
sDNA hydrogel and 0.1 or 0.3 
mM sHexa solution was measured 
and plotted against time.  
Fig. 3. IL-12 release from 
RAW264.7 cells after addition of 
Cryj1, ssODN, sHexa, sDNA 
hydrogel, nsDNA hydrogel, their 
mixture with Cryj1, and the 
Cryj1/sDNA hydrogel at a ratio 
of 20 g Cryj1/100 g DNA. 
IL-12 in the supernatant was 
measured after 16 h of 
incubation with each component. 
Results are expressed as mean  
SD of three determinations. *P < 
0.05, significantly different from 
the Cryj1+ssODN group.  
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Cellular uptake of FITC-Cryj1 by RAW264.7 cells. Fig. 4 shows the mean 
fluorescence intensity (MFI) of RAW264.7 cells incubated at 37°C after addition of 
FITC-Cryj1, FITC-Cryj1+ssODN, FITC-Cryj1+sHexa, FITC-Cryj1+sDNA hydrogel, or 
FITC-Cryj1/sDNA hydrogel. The MFI of cells incubated with the FITC-Cryj1/sDNA 
hydrogel was significantly greater (P < 0.05) than that incubated with any other samples 
examined, suggesting that FITC-Cryj1 loading into sDNA hydrogel increase cellular 




















Distribution and clearance of FITC-Cryj1/sDNA hydrogel after intranasal 
administration to mice. Fig. 5 shows the amount of FITC-Cryj1 and DNA remaining 
in the nasal cavity after intranasal administration of FITC-Cryj1+sHexa or the 
FITC-Cryj1/sDNA hydrogel. In both cases, FITC-Cryj1 and DNA showed similar 
elimination profiles. The half-life of FITC-Cryj1 and DNA in the nasal cavity was 
approximately 3-4 h after administration of the FITC-Cryj1/sDNA hydrogel, whereas it 
was approximately 0.5 h after administration of FITC-Cryj1+sHexa. Fig. 5b shows 
fluorescence images of mouse heads after intranasal administration of Cryj1+sHexa or 
the Cryj1/sDNA hydrogel. To visualize DNA, the sHexa and sDNA hydrogel remaining 
in the cavity were stained with SYBR Gold. This imaging also showed that the sDNA 
hydrogel remained in the nasal cavity for a longer period of time than sHexa.  
 
IL-12 production after intranasal administration of sDNA hydrogel to mice  
Fig. 6 shows the concentration of IL-12 in the serum and NFL at 6 h after intranasal 
administration of saline, ssODN or the sDNA hydrogel at a dose of 50 g/mouse. The 
level of IL-12 in the serum after administration of sDNA hydrogel was significantly 
(P<0.05) greater than that after administration of ssODN, and a similar trend was 
observed in the IL-12 level of the NFL. These results suggest that hydrogel formation 
increases the potency of CpG DNA to induce systemic and mucosal Th1 immune 
responses. 
 
Fig. 4. Uptake of FITC-Cryj1 by 
RAW 264.7 cells. RAW264.7 cells 




FITC-Cryj1+sDNA hydrogel, or 
FITC-Cryj1/sDNA hydrogel at 
concentrations of 20 g/ml 
FITC-Cryj1 and 100 g/ml DNA. 
The amounts of FITC-Cryj1 
associated with cells were 
measured by flow cytometry. 
Results are expressed as mean  
SD of four determinations. *P < 
0.05, significantly different from 






Fig.5. Distribution and clearance of 
FITC-Cryj1/sDNA hydrogel in nasal 
cavity after nasal administration into 
mice. (a) FITC-Cryj1+sHexa or 
FTIC-Cryj1/sDNA hydrogel (50 µg 
DNA, 10 µg Cryj1/mouse) was 
intranasally administrated. NFL was 
collected at the indicated time, and the 
concentration of DNA and Cryj1 from 
FITC-Cryj1+sHexa or the 
FITC-Cryj1/sDNA hydrogel was 
measured and plotted against time. 
Results are expressed as mean  SD of 
three determinations. *P < 0.05, 
significantly different from the 
Cryj1+sHexa group. (b) Cryj1+sHexa 
(left) or the Cryj1/sDNA hydrogel 
(right) was intranasally administered 
after staining of DNA with SYBR 
Gold (50 µg DNA, 10 µg 
Cryj1/mouse). Mice were killed at the 
indicated time and dissected. Then, 
fluorescence distribution around the 
nasal mucosa was photographed. As a 
control, the fluorescence distribution 
before administration was also 






Induction of immune response to Cryj1 by intranasal administration of 
Cryj1/sDNA hydrogel. To investigate the effects of CpG DNA formulation, Cryj1 
loading into the hydrogel, and administration route on the inhibition of allergic reactions, 
the Cryj1-specific Th1 immune response and Cryj1-specific antibody levels after 
immunization were evaluated. Fig. 7a shows the concentration of IL-12 in the 
supernatant of spleen cells after re-stimulation with Cryj1 for 72 h. The spleen cells 
from mice immunized with intranasal Cryj1/sDNA hydrogel produced significantly 
(P<0.05) more IL-12 than those from mice treated with subcutaneous Cryj1, intranasal 
Cryj1, or intranasal Cryj1+ssODN. Fig. 7b shows the concentration of IFN-  in the 
supernatant of spleen cells after re-stimulation with Cryj1 for 72 h. The spleen cells 
from mice immunized with intranasal Cryj1/sDNA hydrogel produced significantly 
(P<0.05) more IFN-  than those from mice treated with intranasal Cryj1, or intranasal 
Cryj1+ssODN. No significant difference in IL-12 and IFN- secretion from 
re-stimulated spleen cells was observed among the different administration routes of 
Cryj1.  
 Intranasal immunization with the Cryj1/sDNA hydrogel induced a higher level of 
Cryj1-specific IgG in the serum and a higher level of Cryj1-specific IgG in the NFL 
compared with intranasal immunization with Cryj1, Cryj1+ssODN, or Cryj1+sHexa 
(Fig. 7c, d). Intranasal immunization with Cryj1/sDNA hydrogel induced a higher level 
of Cryj1-specific IgG in NFL and almost the same level of Cryj1-specific IgG in serum 
compared with subcutaneous immunization with Cryj1 (Fig. 7c, d).  
Fig.6. IL-12 production after intranasal 
administration of the sDNA hydrogel 
to mice. Saline, ssODN, or the sDNA 
hydrogel was administrated 
intranasally to mice (50 µg/mouse). At 
6 h after injection, serum and NFL 
were collected to measure the level of 
IL-12. (a) IL-12 concentration in 
serum. (b) IL-12 concentration in NFL. 
Results are expressed as the mean ± SD 
of five determinations. *P < 0.05, 
significantly different from the ssODN 




Fig. 7. Induction of Cryj1-specific 
immune reactions by intranasal 
administration of Cryj1/sDNA hydrogel. 
Mice were immunized on day 0 and 14 
with Cryj1subcutaneously (s.c.), Cryj1 
intranasally (i.n.), Cryj1+ssODN i.n., 
Cryj1+sHexa i.n. or Cryj1/sDNA hydrogel 
i.n. (50 µg DNA, 10 µg Cryj1/mouse). At 
14 days after the last immunization, spleen 
cells, serum, and NFL were collected. (a) 
Concentration of IL-12 in the supernatant 
of spleen cells at 72 h after re-stimulation 
with Cryj1. (b) Concentration of IFN- in 
the supernatant of spleen cells at 72 h 
after re-stimulation with Cryj1. (c) 
Concentration of Cryj1-specific IgG in 
serum. (d) Concentration of Cryj1-specific 
IgG in NFL. *P < 0.05, significantly 
different from the Cryj1 only group and 
Cryj1+ssODN i.n. group.  
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Suppression of Th2 response by intranasal administration of Cryj1/sDNA 
hydrogel. To investigate the effects of the Cryj1 loading into the sDNA hydrogel on the 
inhibition of allergic sensitivity, serum IgE levels after immunization were evaluated as 
a Th2 response indicator. Fig. 8 shows the concentration of IgE in the serum after 
immunization. The serum IgE level of mice immunized with Cryj1/sDNA hydrogel was 
significantly lower (P < 0.05) than that of mice immunized with Cryj1, suggesting that 
loading of Cryj1 into sDNA hydrogel could attenuate Th2 response, and suppress 
allergic reactions. 
Fig. 8. Supression of Th2 response by 
intranasal administration of Cryj1/sDNA 
hydrogel. Mice were immunized on days 
0, 7 and 14 with Cryj1 intranasally (i.n.), 
Cryj1+ssODN i.n., Cryj1+sHexa i.n. or 
Cryj1/sDNA hydrogel i.n. (50 µg DNA, 10 
µg Cryj1/mouse). At 14 days after the last 
immunization, serum was collected, and 
the concentration of IgE in serum was 
measured. Results are expressed as mean  
SD of six determinations. *P < 0.05, 






Understanding of the mechanisms underlying pollen-induced allergic rhinitis has 
led to the development of vaccines against allergies [19]. Although subcutaneous 
injection of allergens has traditionally been the main immunotherapy method, several 
other formulations including sublingual solutions of JCP extracts and sublingual tablets 
containing grass pollen extracts have been approved in the US, Japan, and other 
countries [18]. In addition, local intranasal delivery of allergens is another promising 
method for administration, and several clinical trials have been conducted worldwide 
[20]. Intranasal immunotherapy could be convenient and ensure patient compliance, 
although current formulations would induce an insufficient immune response because of 
rapid clearance and inefficient uptake of the allergen by nasal immune cells [21]. Thus 
far, CpG DNA has been applied in the intranasal delivery of allergens as an adjuvant for 
allergic rhinitis immunotherapy to induce an efficient immune response [22], but no 
attempts have been made to use CpG DNA as a component for a controlled release 
formation of allergens. Therefore, we examined in this study whether an injectable DNA 
hydrogel consisting of CpG DNA that we previously developed is useful for intranasal 
delivery of Cryj1, the typical allergen of JCP. 
 As demonstrated in our previous study using ovalbumin as a cargo [14], Cryj1 
was slowly released from the DNA hydrogel not only under in vitro conditions but also 
in the nasal cavity of mice (Figs. 2, 5). Because sustained release of antigens is well 
known to effectively induce antigen-specific immune responses [23-24], this slow 
release of Cryj1 from sDNA hydrogel should result in the induction of a high level of 
Cryj1-specific immune responses (Fig. 7). 
 One of our unique findings for nanostructured CpG DNA is that the 
immunostimulatory activity of CpG DNA is dependent on the structural complexity of 
the DNA, which should be at least partly related to increased cellular uptake of CpG 
DNA [13, 25-26]. The higher activity of the sDNA hydrogel, which consists of two sets 
of hexapodna, compared to sHexa (Figs. 3, 6) clearly indicates that multiple units of 
hexapodna would be efficiently taken by cells and recognized by the immune cells 
when the sDNA hydrogel is used. Efficient cellular uptake of DNA hydrogel is 
supposed to result in increased uptake of Cryj1 when added to RAW264.7 cells as 
Cryj1/sDNA hydrogel (Fig. 4). The importance of the immunostimulatory CpG motif in 
the immune responses was also confirmed by the IL-12 release from RAW264.7 cells 
(Fig. 3), which was comparable with the previous results for a DNA hydrogel 
containing OVA [14]. Therefore, the efficient induction of Cryj1-sepcific immune 
response by the Cryj1/sDNA hydrogel (Fig. 7) and the suppression of Th2 response (Fig. 
8) results from (1) the sustained release of Cryj1 from the hydrogel and (2) the high 
immunostimulatory activity of the sDNA hydrogel relative to sHexa. Cryj1-specific IgG 
after intranasal immunization (Fig. 7c, d) did not show significant differences among 
the groups, although it tended to increase by loading Cryj into sDNA hydrogel. This 
could be explained by considering that the immunization increased only some IgG 
subtypes. 
 Nasal sprays are a patient-friendly device for drug administration to the nasal 
cavity. To increase the retention of pharmaceutical agents within the cavity, hydrogels 
are used for the intranasal delivery. Although this approach is promising, the 
administration of hydrogels is not suitable for the spread of the sprayed materials within 
the cavity [27]. Substrates that form gels upon changes in environmental factors, such as 
temperature changes, would solve this problem [28]. In the present study, we 
administered a DNA hydrogel prepared in vitro prior to administration to mice. 
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However, the self-gelling property of the DNA hydrogel enables us to deliver the 
components, i.e., hexapodna in the present case, as a solution and then to obtain the 
DNA hydrogel by spontaneous hybridization of the components within the nasal cavity. 





The present study demonstrated that a CpG motif-containing sDNA hydrogel loaded 
with Cryj1 is useful to induce effective immune responses specific to Cryj1 by 
intranasal administration. Our results also indicate that the sustained release of Cryj1 
from the sDNA hydrogel and the efficient immune stimulation by the sDNA hydrogel 
are the major two factors underlying the Cryj1-specific immune responses. These 
findings introduce the application of DNA hydrogels as a mucosal delivery system for 
shorter immunotherapy with a lower burden. 
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Fig.1. FE-SEM images of the inner structure of sDNA hydrogel and Cryj1/sDNA hydrogel. Left, 
sDNA hydrogel (0.3 mM DNA); center, Cryj1/sDNA hydrogel (0.3 mM DNA); right, 
Cryj1/sDNA hydrogel (0.1 mM DNA). Images were taken using a field-emission scanning 
electron microscope at low (2000, upper panels) and high (5000, lower panels) 
magnifications.  
Fig. 2. Cryj1 release from sDNA hydrogel. FITC-Cryj1 was loaded into the sDNA hydrogel or 
mixed with sHexa solution at a ratio of 1 g Cryj1/5 g DNA, and then placed into the 
upper chamber of the Transwell (0.4-μm pore size) with the bottom chamber containing 
PBS, followed by incubation at 37°C. (a) The fluorescence images of the 
FITC-Cryj1/sDNA hydrogel prepared at DNA concentrations of 0.1 mM (left) and 0.3 mM 
(right) were photographed at the indicated times. (b) The concentration of FITC-Cryj1 
released from 0.1 mM or 0.3 mM sDNA hydrogel and 0.1 or 0.3 mM sHexa solution was 
measured and plotted against time.  
Fig.3. IL-12 release from RAW264.7 cells after addition of Cryj1, ssODN, sHexa, sDNA 
hydrogel, nsDNA hydrogel, their mixture with Cryj1, and Cryj1/sDNA hydrogel at a ratio 
of 20 g Cryj1/100 g DNA. IL-12 in the supernatant was measured after 16 h of 
incubation with each component. Results are expressed as mean  SD of three 
determinations. *P < 0.05, significantly different from the Cryj1+ssODN group.  
Fig. 4. Uptake of FITC-Cryj1 by RAW 264.7 cells. RAW264.7 cells were incubated at 37°C for 
3 h with FITC-Cryj1, FITC-Cryj1+ssODN, FITC-Cryj1+sHexa, FITC-Cryj1+sDNA 
hydrogel, or FITC-Cryj1/sDNA hydrogel at concentrations of 20 g/ml FITC-Cryj1 and 
100 g/ml DNA. The amounts of FITC-Cryj1 associated with cells were measured by flow 
cytometry. Results are expressed as mean  SD of four determinations. *P < 0.05, 
significantly different from all other groups. 
Fig. 5. Distribution and clearance of FITC-Cryj1/sDNA hydrogel in nasal cavity after nasal 
administration into mice. (a) FITC-Cryj1+sHexa or FTIC-Cryj1/sDNA hydrogel (50 µg 
DNA, 10 µg Cryj1/mouse) was intranasally administrated. NFL was collected at the 
indicated time, and the concentration of DNA and Cryj1 from FITC-Cryj1+sHexa or the 
FITC-Cryj1/sDNA hydrogel was measured and plotted against time. Results are expressed 
as mean  SD of three determinations. *P < 0.05, significantly different from the 
Cryj1+sHexa group. (b) Cryj1+sHexa (left) or the Cryj1/sDNA hydrogel (right) was 
intranasally administered after staining of DNA with SYBR Gold (50 µg DNA, 10 µg 
Cryj1/mouse). Mice were killed at the indicated time and dissected. Then, fluorescence 
distribution around the nasal mucosa was photographed. As a control, the fluorescence 
distribution before administration was also photographed (Pre, top). 
Fig. 6. IL-12 production after intranasal administration of the sDNA hydrogel to mice. Saline, 
ssODN, or the sDNA hydrogel was administrated intranasally to mice (50 µg/mouse). At 6 
h after injection, serum and NFL were collected to measure the level of IL-12. (a) IL-12 
concentration in serum. (b) IL-12 concentration in NFL. Results are expressed as the mean 
± SD of five determinations. *P < 0.05, significantly different from the ssODN alone group. 
Fig. 7. Induction of Cryj1-specific immune reactions by intranasal administration of 
Cryj1/sDNA hydrogel. Mice were immunized on day 0 and 14 with Cryj1subcutaneously 
(s.c.), Cryj1 intranasally (i.n.), Cryj1+ssODN i.n., Cryj1+sHexa i.n. or Cryj1/sDNA 
hydrogel i.n. (50 µg DNA, 10 µg Cryj1/mouse). At 14 days after the last immunization, 
spleen cells, serum, and NFL were collected. (a) Concentration of IL-12 in the supernatant 
of spleen cells at 72 h after re-stimulation with Cryj1. (b) Concentration of IFN- in the 
supernatant of spleen cells at 72 h after re-stimulation with Cryj1. (c) Concentration of 
Cryj1-specific IgG in serum. (d) Concentration of Cryj1-specific IgG in NFL. *P < 0.05, 
significantly different from the Cryj1 only group and Cryj1+ssODN i.n. group. 
#
P < 0.05, 
significantly different from all other groups. 
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Fig. 8. Supression of Th2 response by intranasal administration of Cryj1/sDNA hydrogel. Mice 
were immunized on days 0, 7 and 14 with Cryj1 intranasally (i.n.), Cryj1+ssODN i.n., 
Cryj1+sHexa i.n. or Cryj1/sDNA hydrogel i.n. (50 µg DNA, 10 µg Cryj1/mouse). At 14 
days after the last immunization, serum was collected, and the concentration of IgE in 
serum was measured. Results are expressed as mean  SD of six determinations. *P < 0.05, 
significantly different from the Cryj1 only group. 
